Global Generic Anti-cancer Injectables Market Insights, Forecast to 2028

TABLE OF CONTENTS

1 Report Business Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Generic Anti-cancer Injectables Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
  • 1.2.2 Bevacizuma
  • 1.2.3 Rituximab
  • 1.2.4 Herceptin
  • 1.2.5 Paclitaxel
  • 1.2.6 Others
• 1.3 Market by Channel
  • 1.3.1 Global Generic Anti-cancer Injectables Market Size Growth Rate by Channel, 2017 VS 2021 VS 2028
  • 1.3.2 Hospital
  • 1.3.3 Retail
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Generic Anti-cancer Injectables Market Perspective (2017-2028)
• 2.2 Generic Anti-cancer Injectables Growth Trends by Region
  • 2.2.1 Generic Anti-cancer Injectables Market Size by Region: 2017 VS 2021 VS 2028
  • 2.2.2 Generic Anti-cancer Injectables Historic Market Size by Region (2017-2022)
  • 2.2.3 Generic Anti-cancer Injectables Forecasted Market Size by Region (2023-2028)
• 2.3 Generic Anti-cancer Injectables Market Dynamics
  • 2.3.1 Generic Anti-cancer Injectables Industry Trends
  • 2.3.2 Generic Anti-cancer Injectables Market Drivers
  • 2.3.3 Generic Anti-cancer Injectables Market Challenges
  • 2.3.4 Generic Anti-cancer Injectables Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Generic Anti-cancer Injectables Players by Revenue
  • 3.1.1 Global Top Generic Anti-cancer Injectables Players by Revenue (2017-2022)
  • 3.1.2 Global Generic Anti-cancer Injectables Revenue Market Share by Players (2017-2022)
• 3.2 Global Generic Anti-cancer Injectables Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.3 Players Covered: Ranking by Generic Anti-cancer Injectables Revenue
• 3.4 Global Generic Anti-cancer Injectables Market Concentration Ratio
  • 3.4.1 Global Generic Anti-cancer Injectables Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Generic Anti-cancer Injectables Revenue in 2021
• 3.5 Generic Anti-cancer Injectables Key Players Head office and Area Served
• 3.6 Key Players Generic Anti-cancer Injectables Product Solution and Service
• 3.7 Date of Enter into Generic Anti-cancer Injectables Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Generic Anti-cancer Injectables Breakdown Data by Type

• 4.1 Global Generic Anti-cancer Injectables Historic Market Size by Type (2017-2022)
• 4.2 Global Generic Anti-cancer Injectables Forecasted Market Size by Type (2023-2028)

5 Generic Anti-cancer Injectables Breakdown Data by Channel

• 5.1 Global Generic Anti-cancer Injectables Historic Market Size by Channel (2017-2022)
• 5.2 Global Generic Anti-cancer Injectables Forecasted Market Size by Channel (2023-2028)

6 North America

• 6.1 North America Generic Anti-cancer Injectables Market Size (2017-2028)
• 6.2 North America Generic Anti-cancer Injectables Market Size by Type
  • 6.2.1 North America Generic Anti-cancer Injectables Market Size by Type (2017-2022)
  • 6.2.2 North America Generic Anti-cancer Injectables Market Size by Type (2023-2028)
  • 6.2.3 North America Generic Anti-cancer Injectables Market Share by Type (2017-2028)
• 6.3 North America Generic Anti-cancer Injectables Market Size by Channel
  • 6.3.1 North America Generic Anti-cancer Injectables Market Size by Channel (2017-2022)
  • 6.3.2 North America Generic Anti-cancer Injectables Market Size by Channel (2023-2028)
  • 6.3.3 North America Generic Anti-cancer Injectables Market Share by Channel (2017-2028)
• 6.4 North America Generic Anti-cancer Injectables Market Size by Country
  • 6.4.1 North America Generic Anti-cancer Injectables Market Size by Country (2017-2022)
  • 6.4.2 North America Generic Anti-cancer Injectables Market Size by Country (2023-2028)
  • 6.4.3 United States
  • 6.4.4 Canada

7 Europe

• 7.1 Europe Generic Anti-cancer Injectables Market Size (2017-2028)
• 7.2 Europe Generic Anti-cancer Injectables Market Size by Type
  • 7.2.1 Europe Generic Anti-cancer Injectables Market Size by Type (2017-2022)
  • 7.2.2 Europe Generic Anti-cancer Injectables Market Size by Type (2023-2028)
  • 7.2.3 Europe Generic Anti-cancer Injectables Market Share by Type (2017-2028)
• 7.3 Europe Generic Anti-cancer Injectables Market Size by Channel
  • 7.3.1 Europe Generic Anti-cancer Injectables Market Size by Channel (2017-2022)
  • 7.3.2 Europe Generic Anti-cancer Injectables Market Size by Channel (2023-2028)
  • 7.3.3 Europe Generic Anti-cancer Injectables Market Share by Channel (2017-2028)
• 7.4 Europe Generic Anti-cancer Injectables Market Size by Country
  • 7.4.1 Europe Generic Anti-cancer Injectables Market Size by Country (2017-2022)
  • 7.4.2 Europe Generic Anti-cancer Injectables Market Size by Country (2023-2028)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic Countries

8 Asia-Pacific

• 8.1 Asia-Pacific Generic Anti-cancer Injectables Market Size (2017-2028)
• 8.2 Asia-Pacific Generic Anti-cancer Injectables Market Size by Type
  • 8.2.1 Asia-Pacific Generic Anti-cancer Injectables Market Size by Type (2017-2022)
  • 8.2.2 Asia-Pacific Generic Anti-cancer Injectables Market Size by Type (2023-2028)
  • 8.2.3 Asia-Pacific Generic Anti-cancer Injectables Market Share by Type (2017-2028)
• 8.3 Asia-Pacific Generic Anti-cancer Injectables Market Size by Channel
  • 8.3.1 Asia-Pacific Generic Anti-cancer Injectables Market Size by Channel (2017-2022)
  • 8.3.2 Asia-Pacific Generic Anti-cancer Injectables Market Size by Channel (2023-2028)
  • 8.3.3 Asia-Pacific Generic Anti-cancer Injectables Market Share by Channel (2017-2028)
• 8.4 Asia-Pacific Generic Anti-cancer Injectables Market Size by Region
  • 8.4.1 Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2017-2022)
  • 8.4.2 Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2023-2028)
  • 8.4.3 China
  • 8.4.4 Japan
  • 8.4.5 South Korea
  • 8.4.6 Southeast Asia
  • 8.4.7 India
  • 8.4.8 Australia

9 Latin America

• 9.1 Latin America Generic Anti-cancer Injectables Market Size (2017-2028)
• 9.2 Latin America Generic Anti-cancer Injectables Market Size by Type
  • 9.2.1 Latin America Generic Anti-cancer Injectables Market Size by Type (2017-2022)
  • 9.2.2 Latin America Generic Anti-cancer Injectables Market Size by Type (2023-2028)
  • 9.2.3 Latin America Generic Anti-cancer Injectables Market Share by Type (2017-2028)
• 9.3 Latin America Generic Anti-cancer Injectables Market Size by Channel
  • 9.3.1 Latin America Generic Anti-cancer Injectables Market Size by Channel (2017-2022)
  • 9.3.2 Latin America Generic Anti-cancer Injectables Market Size by Channel (2023-2028)
  • 9.3.3 Latin America Generic Anti-cancer Injectables Market Share by Channel (2017-2028)
• 9.4 Latin America Generic Anti-cancer Injectables Market Size by Country
  • 9.4.1 Latin America Generic Anti-cancer Injectables Market Size by Country (2017-2022)
  • 9.4.2 Latin America Generic Anti-cancer Injectables Market Size by Country (2023-2028)
  • 9.4.3 Mexico
  • 9.4.4 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Generic Anti-cancer Injectables Market Size (2017-2028)
• 10.2 Middle East & Africa Generic Anti-cancer Injectables Market Size by Type
  • 10.2.1 Middle East & Africa Generic Anti-cancer Injectables Market Size by Type (2017-2022)
  • 10.2.2 Middle East & Africa Generic Anti-cancer Injectables Market Size by Type (2023-2028)
  • 10.2.3 Middle East & Africa Generic Anti-cancer Injectables Market Share by Type (2017-2028)
• 10.3 Middle East & Africa Generic Anti-cancer Injectables Market Size by Channel
  • 10.3.1 Middle East & Africa Generic Anti-cancer Injectables Market Size by Channel (2017-2022)
  • 10.3.2 Middle East & Africa Generic Anti-cancer Injectables Market Size by Channel (2023-2028)
  • 10.3.3 Middle East & Africa Generic Anti-cancer Injectables Market Share by Channel (2017-2028)
• 10.4 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country
  • 10.4.1 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2017-2022)
  • 10.4.2 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2023-2028)
  • 10.4.3 Turkey
  • 10.4.4 Saudi Arabia
  • 10.4.5 UAE

11 Key Players Profiles

• 11.1 Teva
  • 11.1.1 Teva Company Details
  • 11.1.2 Teva Business Overview
  • 11.1.3 Teva Generic Anti-cancer Injectables Introduction
  • 11.1.4 Teva Revenue in Generic Anti-cancer Injectables Business (2017-2022)
  • 11.1.5 Teva Recent Developments
• 11.2 Viatris
  • 11.2.1 Viatris Company Details
  • 11.2.2 Viatris Business Overview
  • 11.2.3 Viatris Generic Anti-cancer Injectables Introduction
  • 11.2.4 Viatris Revenue in Generic Anti-cancer Injectables Business (2017-2022)
  • 11.2.5 Viatris Recent Developments
• 11.3 Biocon
  • 11.3.1 Biocon Company Details
  • 11.3.2 Biocon Business Overview
  • 11.3.3 Biocon Generic Anti-cancer Injectables Introduction
  • 11.3.4 Biocon Revenue in Generic Anti-cancer Injectables Business (2017-2022)
  • 11.3.5 Biocon Recent Developments
• 11.4 Amgen
  • 11.4.1 Amgen Company Details
  • 11.4.2 Amgen Business Overview
  • 11.4.3 Amgen Generic Anti-cancer Injectables Introduction
  • 11.4.4 Amgen Revenue in Generic Anti-cancer Injectables Business (2017-2022)
  • 11.4.5 Amgen Recent Developments
• 11.5 Sandoz (Novartis)
  • 11.5.1 Sandoz (Novartis) Company Details
  • 11.5.2 Sandoz (Novartis) Business Overview
  • 11.5.3 Sandoz (Novartis) Generic Anti-cancer Injectables Introduction
  • 11.5.4 Sandoz (Novartis) Revenue in Generic Anti-cancer Injectables Business (2017-2022)
  • 11.5.5 Sandoz (Novartis) Recent Developments
• 11.6 Pfizer
  • 11.6.1 Pfizer Company Details
  • 11.6.2 Pfizer Business Overview
  • 11.6.3 Pfizer Generic Anti-cancer Injectables Introduction
  • 11.6.4 Pfizer Revenue in Generic Anti-cancer Injectables Business (2017-2022)
  • 11.6.5 Pfizer Recent Developments
• 11.7 Qilu Pharmaceutical
  • 11.7.1 Qilu Pharmaceutical Company Details
  • 11.7.2 Qilu Pharmaceutical Business Overview
  • 11.7.3 Qilu Pharmaceutical Generic Anti-cancer Injectables Introduction
  • 11.7.4 Qilu Pharmaceutical Revenue in Generic Anti-cancer Injectables Business (2017-2022)
  • 11.7.5 Qilu Pharmaceutical Recent Developments
• 11.8 Jiangsu Hansoh
  • 11.8.1 Jiangsu Hansoh Company Details
  • 11.8.2 Jiangsu Hansoh Business Overview
  • 11.8.3 Jiangsu Hansoh Generic Anti-cancer Injectables Introduction
  • 11.8.4 Jiangsu Hansoh Revenue in Generic Anti-cancer Injectables Business (2017-2022)
  • 11.8.5 Jiangsu Hansoh Recent Developments
• 11.9 CTTQ
  • 11.9.1 CTTQ Company Details
  • 11.9.2 CTTQ Business Overview
  • 11.9.3 CTTQ Generic Anti-cancer Injectables Introduction
  • 11.9.4 CTTQ Revenue in Generic Anti-cancer Injectables Business (2017-2022)
  • 11.9.5 CTTQ Recent Developments
• 11.10 Jiangsu Hengrui
  • 11.10.1 Jiangsu Hengrui Company Details
  • 11.10.2 Jiangsu Hengrui Business Overview
  • 11.10.3 Jiangsu Hengrui Generic Anti-cancer Injectables Introduction
  • 11.10.4 Jiangsu Hengrui Revenue in Generic Anti-cancer Injectables Business (2017-2022)
  • 11.10.5 Jiangsu Hengrui Recent Developments
• 11.11 CSPC
  • 11.11.1 CSPC Company Details
  • 11.11.2 CSPC Business Overview
  • 11.11.3 CSPC Generic Anti-cancer Injectables Introduction
  • 11.11.4 CSPC Revenue in Generic Anti-cancer Injectables Business (2017-2022)
  • 11.11.5 CSPC Recent Developments
• 11.12 Innovent Biologics
  • 11.12.1 Innovent Biologics Company Details
  • 11.12.2 Innovent Biologics Business Overview
  • 11.12.3 Innovent Biologics Generic Anti-cancer Injectables Introduction
  • 11.12.4 Innovent Biologics Revenue in Generic Anti-cancer Injectables Business (2017-2022)
  • 11.12.5 Innovent Biologics Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Author Details
• 13.3 Disclaimer

List of Tables

• Table 1. Global Generic Anti-cancer Injectables Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
• Table 2. Key Players of Bevacizuma
• Table 3. Key Players of Rituximab
• Table 4. Key Players of Herceptin
• Table 5. Key Players of Paclitaxel
• Table 6. Key Players of Others
• Table 7. Global Generic Anti-cancer Injectables Market Size Growth Rate by Channel (US$ Million), 2017 VS 2021 VS 2028
• Table 8. Global Generic Anti-cancer Injectables Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
• Table 9. Global Generic Anti-cancer Injectables Market Size by Region (2017-2022) & (US$ Million)
• Table 10. Global Generic Anti-cancer Injectables Market Share by Region (2017-2022)
• Table 11. Global Generic Anti-cancer Injectables Forecasted Market Size by Region (2023-2028) & (US$ Million)
• Table 12. Global Generic Anti-cancer Injectables Market Share by Region (2023-2028)
• Table 13. Generic Anti-cancer Injectables Market Trends
• Table 14. Generic Anti-cancer Injectables Market Drivers
• Table 15. Generic Anti-cancer Injectables Market Challenges
• Table 16. Generic Anti-cancer Injectables Market Restraints
• Table 17. Global Generic Anti-cancer Injectables Revenue by Players (2017-2022) & (US$ Million)
• Table 18. Global Generic Anti-cancer Injectables Revenue Share by Players (2017-2022)
• Table 19. Global Top Generic Anti-cancer Injectables by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Anti-cancer Injectables as of 2021)
• Table 20. Ranking of Global Top Generic Anti-cancer Injectables Companies by Revenue (US$ Million) in 2021
• Table 21. Global 5 Largest Players Market Share by Generic Anti-cancer Injectables Revenue (CR5 and HHI) & (2017-2022)
• Table 22. Key Players Headquarters and Area Served
• Table 23. Key Players Generic Anti-cancer Injectables Product Solution and Service
• Table 24. Date of Enter into Generic Anti-cancer Injectables Market
• Table 25. Mergers & Acquisitions, Expansion Plans
• Table 26. Global Generic Anti-cancer Injectables Market Size by Type (2017-2022) & (US$ Million)
• Table 27. Global Generic Anti-cancer Injectables Revenue Market Share by Type (2017-2022)
• Table 28. Global Generic Anti-cancer Injectables Forecasted Market Size by Type (2023-2028) & (US$ Million)
• Table 29. Global Generic Anti-cancer Injectables Revenue Market Share by Type (2023-2028)
• Table 30. Global Generic Anti-cancer Injectables Market Size by Channel (2017-2022) & (US$ Million)
• Table 31. Global Generic Anti-cancer Injectables Revenue Share by Channel (2017-2022)
• Table 32. Global Generic Anti-cancer Injectables Forecasted Market Size by Channel (2023-2028) & (US$ Million)
• Table 33. Global Generic Anti-cancer Injectables Revenue Share by Channel (2023-2028)
• Table 34. North America Generic Anti-cancer Injectables Market Size by Type (2017-2022) & (US$ Million)
• Table 35. North America Generic Anti-cancer Injectables Market Size by Type (2023-2028) & (US$ Million)
• Table 36. North America Generic Anti-cancer Injectables Market Size by Channel (2017-2022) & (US$ Million)
• Table 37. North America Generic Anti-cancer Injectables Market Size by Channel (2023-2028) & (US$ Million)
• Table 38. North America Generic Anti-cancer Injectables Market Size by Country (2017-2022) & (US$ Million)
• Table 39. North America Generic Anti-cancer Injectables Market Size by Country (2023-2028) & (US$ Million)
• Table 40. Europe Generic Anti-cancer Injectables Market Size by Type (2017-2022) & (US$ Million)
• Table 41. Europe Generic Anti-cancer Injectables Market Size by Type (2023-2028) & (US$ Million)
• Table 42. Europe Generic Anti-cancer Injectables Market Size by Channel (2017-2022) & (US$ Million)
• Table 43. Europe Generic Anti-cancer Injectables Market Size by Channel (2023-2028) & (US$ Million)
• Table 44. Europe Generic Anti-cancer Injectables Market Size by Country (2017-2022) & (US$ Million)
• Table 45. Europe Generic Anti-cancer Injectables Market Size by Country (2023-2028) & (US$ Million)
• Table 46. Asia Pacific Generic Anti-cancer Injectables Market Size by Type (2017-2022) & (US$ Million)
• Table 47. Asia Pacific Generic Anti-cancer Injectables Market Size by Type (2023-2028) & (US$ Million)
• Table 48. Asia Pacific Generic Anti-cancer Injectables Market Size by Channel (2017-2022) & (US$ Million)
• Table 49. Asia Pacific Generic Anti-cancer Injectables Market Size by Channel (2023-2028) & (US$ Million)
• Table 50. Asia Pacific Generic Anti-cancer Injectables Market Size by Region (2017-2022) & (US$ Million)
• Table 51. Asia Pacific Generic Anti-cancer Injectables Market Size by Region (2023-2028) & (US$ Million)
• Table 52. Latin America Generic Anti-cancer Injectables Market Size by Type (2017-2022) & (US$ Million)
• Table 53. Latin America Generic Anti-cancer Injectables Market Size by Type (2023-2028) & (US$ Million)
• Table 54. Latin America Generic Anti-cancer Injectables Market Size by Channel (2017-2022) & (US$ Million)
• Table 55. Latin America Generic Anti-cancer Injectables Market Size by Channel (2023-2028) & (US$ Million)
• Table 56. Latin America Generic Anti-cancer Injectables Market Size by Country (2017-2022) & (US$ Million)
• Table 57. Latin America Generic Anti-cancer Injectables Market Size by Country (2023-2028) & (US$ Million)
• Table 58. Middle East and Africa Generic Anti-cancer Injectables Market Size by Type (2017-2022) & (US$ Million)
• Table 59. Middle East and Africa Generic Anti-cancer Injectables Market Size by Type (2023-2028) & (US$ Million)
• Table 60. Middle East and Africa Generic Anti-cancer Injectables Market Size by Channel (2017-2022) & (US$ Million)
• Table 61. Middle East and Africa Generic Anti-cancer Injectables Market Size by Channel (2023-2028) & (US$ Million)
• Table 62. Middle East and Africa Generic Anti-cancer Injectables Market Size by Country (2017-2022) & (US$ Million)
• Table 63. Middle East and Africa Generic Anti-cancer Injectables Market Size by Country (2023-2028) & (US$ Million)
• Table 64. Teva Company Details
• Table 65. Teva Business Overview
• Table 66. Teva Generic Anti-cancer Injectables Product
• Table 67. Teva Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
• Table 68. Teva Recent Developments
• Table 69. Viatris Company Details
• Table 70. Viatris Business Overview
• Table 71. Viatris Generic Anti-cancer Injectables Product
• Table 72. Viatris Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
• Table 73. Viatris Recent Developments
• Table 74. Biocon Company Details
• Table 75. Biocon Business Overview
• Table 76. Biocon Generic Anti-cancer Injectables Product
• Table 77. Biocon Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
• Table 78. Biocon Recent Developments
• Table 79. Amgen Company Details
• Table 80. Amgen Business Overview
• Table 81. Amgen Generic Anti-cancer Injectables Product
• Table 82. Amgen Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
• Table 83. Amgen Recent Developments
• Table 84. Sandoz (Novartis) Company Details
• Table 85. Sandoz (Novartis) Business Overview
• Table 86. Sandoz (Novartis) Generic Anti-cancer Injectables Product
• Table 87. Sandoz (Novartis) Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
• Table 88. Sandoz (Novartis) Recent Developments
• Table 89. Pfizer Company Details
• Table 90. Pfizer Business Overview
• Table 91. Pfizer Generic Anti-cancer Injectables Product
• Table 92. Pfizer Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
• Table 93. Pfizer Recent Developments
• Table 94. Qilu Pharmaceutical Company Details
• Table 95. Qilu Pharmaceutical Business Overview
• Table 96. Qilu Pharmaceutical Generic Anti-cancer Injectables Product
• Table 97. Qilu Pharmaceutical Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
• Table 98. Qilu Pharmaceutical Recent Developments
• Table 99. Jiangsu Hansoh Company Details
• Table 100. Jiangsu Hansoh Business Overview
• Table 101. Jiangsu Hansoh Generic Anti-cancer Injectables Product
• Table 102. Jiangsu Hansoh Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
• Table 103. Jiangsu Hansoh Recent Developments
• Table 104. CTTQ Company Details
• Table 105. CTTQ Business Overview
• Table 106. CTTQ Generic Anti-cancer Injectables Product
• Table 107. CTTQ Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
• Table 108. CTTQ Recent Developments
• Table 109. Jiangsu Hengrui Company Details
• Table 110. Jiangsu Hengrui Business Overview
• Table 111. Jiangsu Hengrui Generic Anti-cancer Injectables Product
• Table 112. Jiangsu Hengrui Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
• Table 113. Jiangsu Hengrui Recent Developments
• Table 114. CSPC Company Details
• Table 115. CSPC Business Overview
• Table 116. CSPC Generic Anti-cancer Injectables Product
• Table 117. CSPC Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
• Table 118. CSPC Recent Developments
• Table 119. Innovent Biologics Company Details
• Table 120. Innovent Biologics Business Overview
• Table 121. Innovent Biologics Generic Anti-cancer Injectables Product
• Table 122. Innovent Biologics Revenue in Generic Anti-cancer Injectables Business (2017-2022) & (US$ Million)
• Table 123. Innovent Biologics Recent Developments
• Table 124. Research Programs/Design for This Report
• Table 125. Key Data Information from Secondary Sources
• Table 126. Key Data Information from Primary Sources

List of Figures

• Figure 1. Global Generic Anti-cancer Injectables Market Share by Type: 2021 VS 2028
• Figure 2. Bevacizuma Features
• Figure 3. Rituximab Features
• Figure 4. Herceptin Features
• Figure 5. Paclitaxel Features
• Figure 6. Others Features
• Figure 7. Global Generic Anti-cancer Injectables Market Share by Channel: 2021 VS 2028
• Figure 8. Hospital Case Studies
• Figure 9. Retail Case Studies
• Figure 10. Generic Anti-cancer Injectables Report Years Considered
• Figure 11. Global Generic Anti-cancer Injectables Market Size (US$ Million), Year-over-Year: 2017-2028
• Figure 12. Global Generic Anti-cancer Injectables Market Size, (US$ Million), 2017 VS 2021 VS 2028
• Figure 13. Global Generic Anti-cancer Injectables Market Share by Region: 2021 VS 2028
• Figure 14. Global Generic Anti-cancer Injectables Market Share by Players in 2021
• Figure 15. Global Top Generic Anti-cancer Injectables Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Anti-cancer Injectables as of 2021)
• Figure 16. The Top 10 and 5 Players Market Share by Generic Anti-cancer Injectables Revenue in 2021
• Figure 17. North America Generic Anti-cancer Injectables Market Size YoY (2017-2028) & (US$ Million)
• Figure 18. North America Generic Anti-cancer Injectables Market Size Market Share by Type (2017-2028)
• Figure 19. North America Generic Anti-cancer Injectables Market Size Market Share by Channel (2017-2028)
• Figure 20. North America Generic Anti-cancer Injectables Market Size Share by Country (2017-2028)
• Figure 21. United States Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 22. Canada Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 23. Europe Generic Anti-cancer Injectables Market Size YoY (2017-2028) & (US$ Million)
• Figure 24. Europe Generic Anti-cancer Injectables Market Size Market Share by Type (2017-2028)
• Figure 25. Europe Generic Anti-cancer Injectables Market Size Market Share by Channel (2017-2028)
• Figure 26. Europe Generic Anti-cancer Injectables Market Size Share by Country (2017-2028)
• Figure 27. Germany Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 28. France Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 29. U.K. Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 30. Italy Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 31. Russia Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 32. Nordic Countries Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 33. Asia-Pacific Generic Anti-cancer Injectables Market Size YoY (2017-2028) & (US$ Million)
• Figure 34. Asia Pacific Generic Anti-cancer Injectables Market Size Market Share by Type (2017-2028)
• Figure 35. Asia Pacific Generic Anti-cancer Injectables Market Size Market Share by Channel (2017-2028)
• Figure 36. Asia Pacific Generic Anti-cancer Injectables Market Size Share by Region (2017-2028)
• Figure 37. China Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 38. Japan Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 39. South Korea Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 40. Southeast Asia Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 41. India Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 42. Australia Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)

List of Figures

• Figure 43. Latin America Generic Anti-cancer Injectables Market Size YoY (2017-2028) & (US$ Million)
• Figure 44. Latin America Generic Anti-cancer Injectables Market Size Market Share by Type (2017-2028)
• Figure 45. Latin America Generic Anti-cancer Injectables Market Size Market Share by Channel (2017-2028)
• Figure 46. Latin America Generic Anti-cancer Injectables Market Size Share by Country (2017-2028)
• Figure 47. Mexico Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 48. Brazil Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 49. Middle East & Africa Generic Anti-cancer Injectables Market Size YoY (2017-2028) & (US$ Million)
• Figure 50. Middle East and Africa Generic Anti-cancer Injectables Market Size Market Share by Type (2017-2028)
• Figure 51. Middle East and Africa Generic Anti-cancer Injectables Market Size Market Share by Channel (2017-2028)
• Figure 52. Middle East and Africa Generic Anti-cancer Injectables Market Size Share by Country (2017-2028)
• Figure 53. Turkey Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 54. Saudi Arabia Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 55. UAE Generic Anti-cancer Injectables Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 56. Teva Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
• Figure 57. Viatris Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
• Figure 58. Biocon Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
• Figure 59. Amgen Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
• Figure 60. Sandoz (Novartis) Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
• Figure 61. Pfizer Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
• Figure 62. Qilu Pharmaceutical Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
• Figure 63. Jiangsu Hansoh Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
• Figure 64. CTTQ Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
• Figure 65. Jiangsu Hengrui Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
• Figure 66. CSPC Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
• Figure 67. Innovent Biologics Revenue Growth Rate in Generic Anti-cancer Injectables Business (2017-2022)
• Figure 68. Bottom-up and Top-down Approaches for This Report
• Figure 69. Data Triangulation
• Figure 70. Key Executives Interviewed